1.The Expression of NMDA Receptor 1 Correlates with Clinicopathological Parameters in Cutaneous Squamous Cell Carcinoma.
Minju KANG ; Jae Hoon CHO ; Ja Kyung KOO ; Sun Up NOH ; Mi Yeon KIM ; Hoon KANG ; Shin Taek OH ; Hyung Ok KIM ; Young Min PARK
Annals of Dermatology 2009;21(4):382-388
BACKGROUND: Ionotropic glutamate receptors of the N-methyl-D-aspartate receptor (NMDAR) type are expressed on keratinocytes and play a role in the proliferation, differentiation, and cornification of keratinocytes. However, the expression profile of NMDAR and its role in cutaneous malignancy is unclear. OBJECTIVE: We analyzed the expression of NMDAR-1 in cutaneous squamous cell carcinoma (SCC) and investigated the relationship between NMDAR-1 expression and clinicopathological parameters. METHODS: Thirty-two patients with biopsy-proven cutaneous SCC were enrolled in this study. Each patient was analyzed for tumor diameter, location, local recurrence, and metastasis by conducting a chart review. The SCC specimens were histologically divided into differentiated and undifferentiated groups based on Broders' system. NMDAR-1 expression was examined by performing immunohistochemistry, and the relative staining intensity in the SCCs was graded into 5 levels. According to the staining intensity of NMDAR-1, the specimens were categorized into two groups: the higher group and the lower group. RESULTS: Fifteen (88%) of 17 tumors in the higher group were differentiated SCC, whereas 14 (93%) of 15 tumors in the lower group were undifferentiated SCC. In addition, NMDAR-1 expression was inversely correlated with metastasis (p=0.049). Local recurrence was associated with a lower staining intensity, but the results were not statistically significant. CONCLUSION: Our results demonstrate that NMDAR-1 expression in cutaneous SCC is significantly correlated with its differentiation and metastasis. Therefore, it may be a prognostic indicator for cutaneous SCC.
Carcinoma, Squamous Cell
;
Humans
;
Immunohistochemistry
;
Keratinocytes
;
N-Methylaspartate
;
Neoplasm Metastasis
;
Receptors, Ionotropic Glutamate
;
Recurrence
2.Therapeutic Effects of Topical Application of Ozone on Acute Cutaneous Wound Healing.
Hee Su KIM ; Sun Up NOH ; Ye Won HAN ; Kyoung Moon KIM ; Hoon KANG ; Hyung Ok KIM ; Young Min PARK
Journal of Korean Medical Science 2009;24(3):368-374
This study was undertaken to evaluate the therapeutic effects of topical ozonated olive oil on acute cutaneous wound healing in a guinea pig model and also to elucidate its therapeutic mechanism. After creating full-thickness skin wounds on the backs of guinea pigs by using a 6 mm punch biopsy, we examined the wound healing effect of topically applied ozonated olive oil (ozone group), as compared to the pure olive oil (oil group) and non-treatment (control group). The ozone group of guinea pig had a significantly smaller wound size and a residual wound area than the oil group, on days 5 (P<0.05) and 7 (P<0.01 and P<0.05) after wound surgery, respectively. Both hematoxylin-eosin staining and Masson-trichrome staining revealed an increased intensity of collagen fibers and a greater number of fibroblasts in the ozone group than that in the oil group on day 7. Immunohistochemical staining demonstrated upregulation of platelet derived growth factor (PDGF), transforming growth factor-beta (TGF-beta) and vascular endothelial growth factor (VEGF) expressions, but not fibroblast growth factor expression in the ozone group on day 7, as compared with the oil group. In conclusion, these results demonstrate that topical application of ozonated olive oil can accelerate acute cutaneous wound repair in a guinea pig in association with the increased expression of PDGF, TGF-beta, and VEGF.
Acute Disease
;
Administration, Topical
;
Animals
;
Female
;
Guinea Pigs
;
Ozone/administration & dosage/*therapeutic use
;
Plant Oils/administration & dosage/therapeutic use
;
Platelet-Derived Growth Factor/metabolism
;
Skin/*drug effects/pathology
;
Transforming Growth Factor beta/metabolism
;
Vascular Endothelial Growth Factor A/metabolism
;
Wound Healing/*drug effects
3.Assessment of Quality of Life and Safety in Postmenopausal Breast Cancer Patients Receiving Letrozole as an Early Adjuvant Treatment.
Yongsik JUNG ; Soo Jung LEE ; Juneyoung LEE ; Woo Chul NOH ; Seok Jin NAM ; Byeong Woo PARK ; Young Tae BAE ; Sung Soo KANG ; Heung Kyu PARK ; Jung Han YOON ; Je Ryong KIM ; Se Hun CHO ; Lee Su KIM ; Byung In MOON ; Sung Hoo JUNG ; Chol Wan LIM ; Sung Yong KIM ; Ho Yong PARK ; Jeongyoon SONG ; Kwang Man LEE ; Sung Hwan PARK ; Joon JEONG ; Hae Lin PARK ; Sung Won KIM ; Beom Seok KWAK ; Sun Hee KANG ; Young Up CHO ; Geum Hee GWAK ; Yong Lae PARK ; Sang Wook KIM ; Sehwan HAN
Journal of Breast Cancer 2018;21(2):182-189
PURPOSE: There are few reports from Asian countries about the long-term results of aromatase inhibitor adjuvant treatment for breast cancer. This observational study aimed to evaluate the long-term effects of letrozole in postmenopausal Korean women with operable breast cancer. METHODS: Self-reported quality of life (QoL) scores were serially assessed for 3 years during adjuvant letrozole treatment using the Korean version of the Functional Assessment of Cancer Therapy-Breast questionnaires (version 3). Changes in bone mineral density (BMD) and serum cholesterol levels were also examined. RESULTS: All 897 patients received the documented informed consent form and completed a baseline questionnaire before treatment. Adjuvant chemotherapy was administered to 684 (76.3%) subjects, and 410 (45.7%) and 396 (44.1%) patients had stage I and II breast cancer, respectively. Each patient completed questionnaires at 3, 6, 12, 18, 24, 30, and 36 months after enrollment. Of 897 patients, 749 (83.5%) completed the study. The dropout rate was 16.5%. The serial trial outcome index, the sum of the physical and functional well-being subscales, increased gradually and significantly from baseline during letrozole treatment (p<0.001). The mean serum cholesterol level increased significantly from 199 to 205 after 36 months (p=0.042). The mean BMD significantly decreased from −0.39 at baseline to −0.87 after 36 months (p<0.001). CONCLUSION: QoL gradually improved during letrozole treatment. BMD and serum cholesterol level changes were similar to those in Western countries, indicating that adjuvant letrozole treatment is well tolerated in Korean women, with minimal ethnic variation.
Aromatase
;
Asian Continental Ancestry Group
;
Bone Density
;
Breast Neoplasms*
;
Breast*
;
Chemotherapy, Adjuvant
;
Cholesterol
;
Consent Forms
;
Female
;
Humans
;
Observational Study
;
Quality of Life*